Emergent BioSolutions Inc.

NYSE:EBS

Biotechnology

Healthcare
$5.50 -2.58%

-$0.21 today

Market cap
$282.78M
Beta
2.33
P/E (TTM)
-47.9
EPS (TTM)
-$0.17
52W Low $5.62High $14.06

Volume 0.82M

Average 0.78M

EBS Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Emergent BioSolutions Inc.NYSE: EBS

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $10.5M fell 30.9% year over year, in line with the -30.6% change in trailing-twelve-month research & development. Sequentially, it fell 13.2% from the prior quarter. Over 3 fiscal years it compounded at -34.1% a year.

Context

  • Research & development amounted to 7.2% of revenue in FY2025, up 0.5 pp from a year earlier.
  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -30.9% toward the trailing-twelve-month pace of -30.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$10.5M-13.2% QoQ
Last fiscal yearDec 2025
$53.8M-23.9% YoY
LTMMar 2026
$49.1M-30.6% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-30.9%——
1 year-23.9%——
3-year CAGR-34.1%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
53.8M USD
Year-over-year change
-23.9%
4-year CAGR
-30.8%

Research & Development vs competitors

How EBS compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -30.6% is the 10th highest of 11, against a peer median of -0.2%.
  • Research & development amounts to 7.3% of revenue for EBS, versus a peer median of 12.2%.
EBS Competitors
Research & Development for EBS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SIGASIGA Technologies, Inc.LTM Mar 2026$2.7T USD+25130615.4%-33.8%2884018.5%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$176.31M USD+40.8%+24.2%—
CMPSCOMPASS Pathways plcLTM Mar 2026$110.07M USD-12.0%+22.1%—
PRTAProthena Corporation plcLTM Mar 2026$96.67M USD-53.8%-0.2%166.8%
EBSEmergent BioSolutions Inc.LTM Mar 2026$49.1M USD-30.6%-34.1%7.3%
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$49.06M USD+2.0%+3.9%9.6%
ESPREsperion Therapeutics, Inc.LTM Mar 2026$44.28M USD-2.4%-26.2%10.6%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$37.44M USD+64.5%+11.3%—
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$36.54M USD+41.7%-17.9%12.2%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026$16.04M USD-18.6%-0.6%31.9%
SNDLSNDL Inc.LTM Mar 2026CA$393K CAD-3.9%-41.5%0.0%
Peer median (excluding EBS) —-0.2%-0.4%12.2%

Competitors are the stored peer set for EBS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.77B1.12B1.05B1.04B742.9M
Cost of Revenue980.4M644.5M689.3M668.2M392.3M
Gross Profit793.2M473M360M375.4M350.6M
Gross Margin44.7%42.3%34.3%36.0%47.2%
Research & Development235.2M188.3M111.4M70.7M53.8M
Selling, General & Admin348.7M339.5M356.7M298.7M186.6M
Operating Expenses451.8M643M1.09B484.1M240.4M
Depreciation & Amortization118.2M125M121.1M105.6M98.3M
EBITDA504.2M15.7M(47M)53.4M240.4M
EBITDA Margin28.4%1.4%-4.5%5.1%32.4%
Operating Income341.4M(170M)(726.4M)(108.7M)110.2M
Operating Margin19.2%-15.2%-69.2%-10.4%14.8%
Interest Income00000
Interest Expense34.5M37.3M87.9M71M59.3M
Other Income / Expenses(38.2M)(49M)(4.8M)(34.2M)(27.4M)
Income Before Tax303.2M(219M)(731.2M)(142.9M)82.8M
Pre-Tax Margin17.1%-19.6%-69.7%-13.7%11.1%
Income Tax Expense83.7M(7.4M)29.3M47.7M30.2M
Net Income219.5M(211.6M)(760.5M)(190.6M)52.6M
Net Margin12.4%-18.9%-72.5%-18.3%7.1%
EPS (Basic)4.10(4.22)(14.85)(3.60)0.98
EPS (Diluted)4.06(4.22)(14.85)(3.60)0.93
Weighted Avg Shares53.5M50.1M51.2M53M53.5M
Weighted Avg Shares (Diluted)54.1M50.1M51.2M53M56.7M

Emergent BioSolutions Inc.

NYSE:EBS

Intrinsic Alpha fair value

Locked

Current Price

$5.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.